PharmAust (ASX:PAA) Debt-to-Revenue : N/A (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is PharmAust Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

PharmAust's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. PharmAust's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. PharmAust's annualized Revenue for the quarter that ended in Dec. 2023 was A$0.00 Mil.

PharmAust Debt-to-Revenue Historical Data

The historical data trend for PharmAust's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmAust Debt-to-Revenue Chart

PharmAust Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Revenue

Get a 7-Day Free Trial

0.09

0.46

0.60

0.41

0.37

PharmAust Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.37	0.41	0.29	0.58	N/A

Competitive Comparison of PharmAust's Debt-to-Revenue

For the Biotechnology subindustry, PharmAust's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmAust's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmAust's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where PharmAust's Debt-to-Revenue falls into.

PharmAust Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

PharmAust's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.158	+	0.891)	/	2.824
	=	0.37

PharmAust's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

PharmAust Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of PharmAust's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmAust (ASX:PAA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmAust Ltd (ASX:PAA) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

ECQ:Germany ECQ:Germany

Address

1 Kyle Way, Suite 116, Claremont, Perth, WA, AUS, 6010

Website

https://www.pharmaust.com

PharmAust Ltd operates as a drug discovery and development company in Australia, Switzerland, and internationally. It develops drug discovery intellectual property for the treatment of various cancers in humans and animals. The company offers Monepantel and Albendazole, which are in Phase II clinical trials for the treatment of cancer. It also provides medicinal and synthetic chemistry services on a contract basis to the drug discovery and pharmaceutical industries.